ArticleImmunity2015
Distinct mechanisms of tumor resistance to NK killing: of mice and men.
Article in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Role of the androgen receptor in melanoma aggressiveness.Cell death & disease · 2025Article
- Basic immunologic study as a foundation for engineered therapeutic development.Pharmacology research & perspectives · 2024Review
- Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses.Clinical and experimental medicine · 2023Article
- Expression of CISH, an Inhibitor of NK Cell Function, Increases in Association with Ovarian Cancer Development and Progression.Biomedicines · 2023Article
- Challenges and opportunities in the islet transplantation microenvironment: a comprehensive summary of inflammatory cytokine, immune cells, and vascular endothelial cells.Frontiers in immunology · 2023Review
- Metformin promotes antitumor activity of NK cells via overexpression of miRNA-150 and miRNA-155.American journal of translational research · 2023Article
- Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- Mass Production of Highly Active NK Cells for Cancer Immunotherapy in a GMP Conform Perfusion Bioreactor.Frontiers in bioengineering and biotechnology · 2019Article
- Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer.Cell death & disease · 2017Article
- T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.Oncotarget · 2016Article
- Dynamics of the spleen and its significance in a murine H22 orthotopic hepatoma model.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.Oncoimmunology · 2016Article
- Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Tumors cells can release natural killer (NK) cell ligands for activating receptor NKG2D that are thought to inhibit NK cell function. In a recent issue of Science, Deng et al. (2015) show that, unexpectedly, a soluble NKG2D ligand can enhance anti-tumor NK cell activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.